Factor VIII Concept

subject area of

• 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII  Journal Articles
• FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies  Journal Articles
• A Canadian survey of self‐infusion practices in persons with haemophilia A  Journal Articles
• A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada  Journal Articles
• A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A  Journal Articles
• A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients  Journal Articles
• A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients  Journal Articles
• A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates  Journal Articles
• A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.  Journal Articles
• A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose  Journal Articles
• A survey of factor prophylaxis in the Canadian haemophilia A population  Journal Articles
• A therapeutic alternative for haemophiliacs with inhibitors  Journal Articles
• A von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice  Journal Articles
• AIDS in a patient with hemophilia receiving mainly cryoprecipitate.  Journal Articles
• Acquired Hemophilia A  Journal Articles
• Acquired hemophilia masked by warfarin therapy  Journal Articles
• Acute Effects with Reference to Thrombogenicity and Liver Toxicity after Injection of Different Coagulation Factor Concentrates  Journal Articles
• Adjusted dose continuous infusion of factor VIII in patients with haemophilia A  Journal Articles
• Adsorption of immunoglobulin G and anti-Factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes  Journal Articles
• Angiomatosis of skin with local intravascular immunoglobulin deposits, associated with monoclonal gammopathy. A potential cutaneous marker for B‐chronic lymphocytic leukemia  Journal Articles
• Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward  Journal Articles
• Approaches to the measurement of the response to Factor VIII concentrate infusion  Journal Articles
• Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa  Journal Articles
• Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis  Journal Articles
• BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial  Journal Articles
• Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review  Journal Articles
• Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?  Journal Articles
• Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada  Journal Articles
• Canadian multi‐institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT  Journal Articles
• Carrier detection of haemophilia A using DNA markers in families with an isolated affected male  Journal Articles
• Central venous access device insertion and perioperative management of patients with severe haemophilia A  Journal Articles
• Changes in coagulation factor activity and content of di(2‐ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing  Journal Articles
• Characterization of viability and proliferation of alginate‐poly‐L‐lysine–alginate encapsulated myoblasts using flow cytometry  Journal Articles
• Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users  Journal Articles
• Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice  Journal Articles
• Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?  Journal Articles
• Comparing bleed frequency and factor concentrate use between haemophilia A and B patients  Journal Articles
• Comparing hand‐held computers and paper diaries for haemophilia home therapy: a randomized trial  Journal Articles
• Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A  Journal Articles
• Concentrate‐related inhibitor risk: is a difference always real?  Journal Articles
• Continuous infusion  Conferences
• Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience  Journal Articles
• Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time  Journal Articles
• Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada  Journal Articles
• Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus  Journal Articles
• Design and assessment of clinical trials on continuous infusion.  Conferences
• Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup  Journal Articles
• Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization  Conferences
• Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project  Journal Articles
• Diagnosis and treatment of intracranial hemorrhage in children with hemophilia  Journal Articles
• Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment  Journal Articles
• Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Journal Articles
• Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Journal Articles
• Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A  Journal Articles
• Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.  Journal Articles
• Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A  Journal Articles
• Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.  Journal Articles
• Effects of factor VIII concentrates on the immune system in hemophilic patients  Journal Articles
• Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease  Journal Articles
• Efficacy and safety evaluation of Fanhdi^®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study  Journal Articles
• Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review  Journal Articles
• Emicizumab state‐of‐the‐art update  Journal Articles
• Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen–deuterium exchange mass spectrometry  Journal Articles
• Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients  Journal Articles
• Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH  Journal Articles
• Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor  Journal Articles
• Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS)  Journal Articles
• Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment  Journal Articles
• Extending the pre-processing holding time of whole blood beyond 48 h reduces coagulation FVIII activity and immunoglobulin G content of recovered plasma  Journal Articles
• Factor VIII Products and Inhibitors in Severe Hemophilia A  Journal Articles
• Factor VIII concentrate for hemophilia: comparison of two heat-treated products.  Journal Articles
• Factor VIII products and inhibitors in severe hemophilia A.  Journal Articles
• Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes  Journal Articles
• Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice  Journal Articles
• Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach  Journal Articles
• First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study  Journal Articles
• Gene Therapy for Hemophilia  Journal Articles
• Global data and haemophilia care trends: commentary  Journal Articles
• Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements  Journal Articles
• Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A  Journal Articles
• Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.  Journal Articles
• Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/factor VIII concentrate  Journal Articles
• Hepatitis C Infection in Patients With Hemophilia: Results of a National Survey  Journal Articles
• Heterogeneity of information regarding inhibitors in the product monographs of antihaemophilic factors in North America  Journal Articles
• Heterogeneity of the immune response to adenovirus‐mediated factor VIII gene therapy in different inbred hemophilic mouse strains  Journal Articles
• High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs  Journal Articles
• High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis  Journal Articles
• High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance  Journal Articles
• Hypercoagulability.  Journal Articles
• IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII  Journal Articles
• Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.  Journal Articles
• Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B  Journal Articles
• Immunodepletion of human plasma factor VIII  Journal Articles
• Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients  Journal Articles
• Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity  Journal Articles
• Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products  Journal Articles
• Inhibitor development in haemophilia according to concentrate  Journal Articles
• Inhibitor development in non-severe haemophilia across Europe  Journal Articles
• Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression  Journal Articles
• Joint WFH‐ISTH session: issues in clinical trial design  Journal Articles
• Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans  Journal Articles
• Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more  Journal Articles
• Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients  Journal Articles
• Loss of factor VIII activity during storage in PVC containers due to adsorption  Journal Articles
• Low Dose Prophylaxis vis-a-vis on-Demand Treatment Strategies for Hemophilia: A Cost Effective and Disability Attenuating Approach.  Journal Articles
• Low prevalence of inhibitor antibodies in the Canadian haemophilia population  Journal Articles
• Lower-dose emicizumab prophylaxis: can less be more?  Journal Articles
• Management of Inheritedvon Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients  Journal Articles
• Management of bleeding disorders: basic science  Journal Articles
• Mechanisms for Inhibition of the Generation of Thrombin Activity by Sulfated Polysaccharides^a  Journal Articles
• Modulation of the Enzymatic Activity of α-Thrombin by Polyanions: Consequences on Intrinsic Activation of Factor V and Factor VIII  Journal Articles
• Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience  Journal Articles
• Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates  Journal Articles
• Multiple Joint Procedures in a Single Operative Session on Hemophilic Patients  Journal Articles
• Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study  Journal Articles
• Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran  Conferences
• Need for a new paediatric post thrombotic sequelae outcome measure for non-extremity thrombosis  Journal Articles
• Nonviral Gene Therapy Approaches to Hemophilia  Journal Articles
• North American Study of Factor VIII Concentrate Potency  Journal Articles
• ON THE BLEEDER: A CASE OF VON WILLEBRAND'S DISEASE AND ITS TREATMENT WITH HUMAN ANTI-HAEMOPHILIC FACTOR.  Journal Articles
• ON THE BLEEDER: A CASE OF VON WILLEBRAND'S DISEASE AND ITS TREATMENT WITH HUMAN ANTI‐HÆMOPHILIC FACTOR  Journal Articles
• Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma‐derived solvent‐detergent factor VIII concentrate  Journal Articles
• On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome  Journal Articles
• Oral Corticosteroid Therapy as an Adjuvant Treatment for Acute Bleeding in Hemophilia Patients With High Titer Inhibitors  Journal Articles
• Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care  Journal Articles
• Orthotopic liver transplantation in a patient with combined hemophilia A and B  Journal Articles
• Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM  Journal Articles
• Patterns of joint damage in severe haemophilia A treated with prophylaxis  Journal Articles
• Performance of recalibrated ReFacto^® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto^® (B‐domain deleted recombinant factor VIII)  Journal Articles
• Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study  Journal Articles
• Pharmacokinetics of recombinant and plasma‐derived factor VIII products in paediatric patients with severe haemophilia A  Journal Articles
• Placental Barrier to Coagulation Factors: Its Relevance to the Coagulation Defect at Birth and to Haemorrhage in the Newborn  Journal Articles
• Plasma-derived biological medicines used to promote haemostasis  Journal Articles
• Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)  Journal Articles
• Platelet activation induced by porcine factor VIII (HYATE:C)  Journal Articles
• Prolonged Prothrombin Time and Partial Thromboplastin Time in Disseminated Intravascular Coagulation not Due to Deficiency of Factors V and VIII  Journal Articles
• Prolonged hemorrhagic shock does not impair regeneration of plasma coagulant masses in the rabbit  Journal Articles
• Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.  Journal Articles
• Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature  Journal Articles
• Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial  Journal Articles
• Pulmonary Hypertension in Hemophilia  Journal Articles
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review  Journal Articles
• Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study  Journal Articles
• Recombinant factor VIII concentrate  Journal Articles
• Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors  Journal Articles
• Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere‐FRA(X)‐DXS15‐DXS52‐F8C‐telomere  Journal Articles
• Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH  Journal Articles
• Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A  Journal Articles
• Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates  Journal Articles
• Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice  Journal Articles
• Review of pumps for continuous infusion of coagulation factor concentrates: what are the options?  Conferences
• Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study  Journal Articles
• Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients  Conferences
• Safety and Efficacy of Continuous Infusion of a Combined Factor VIII – von Willebrand Factor (vWF) Concentrate (Haemate-P™) in Patients with von Willebrand Disease  Journal Articles
• Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting  Journal Articles
• Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study  Journal Articles
• Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study  Journal Articles
• Stability of factor VIII concentrates after reconstitution  Journal Articles
• Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw  Journal Articles
• Suggestions for the management of factor VIII inhibitors  Journal Articles
• Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature  Journal Articles
• Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy  Journal Articles
• Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity  Journal Articles
• Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics  Journal Articles
• Switching patients in the age of long-acting recombinant products?  Journal Articles
• Switching to extended half‐life products in Canada – preliminary data  Journal Articles
• THE TREATMENT OF HAEMOPHILIA A WITH ANTI‐HAEMOPHILIC FACTOR  Journal Articles
• Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort  Journal Articles
• Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study  Journal Articles
• Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement  Journal Articles
• Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database  Journal Articles
• Thalidomide‐prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10  Journal Articles
• The APTT Response of Pregnant Plasma to Unfractionated Heparin  Journal Articles
• The Influence of Helicobacter pylori Status on Circulating Levels of the Coagulation Factors Fibrinogen, von Willebrand Factor, Factor VII, and Factor VIII  Journal Articles
• The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters  Journal Articles
• The Structural Integrity of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII  Journal Articles
• The World Federation of Hemophilia Annual Global Survey 1999‐2018  Journal Articles
• The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios  Journal Articles
• The current state of adverse event reporting in hemophilia  Journal Articles
• The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies  Journal Articles
• The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A  Journal Articles
• The factor VIII-independent activation of factor X by factors IXa and VII in plasma  Journal Articles
• The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice  Journal Articles
• The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro  Journal Articles
• The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III  Journal Articles
• The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey  Journal Articles
• The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A  Journal Articles
• Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A  Journal Articles
• Thrombin and Antithrombotics  Journal Articles
• Thrombin generation in vitro in the presence of by‐passing agents in siblings with severe haemophilia A  Journal Articles
• Thrombocytopenia in Preeclampsia and Eclampsia  Journal Articles
• Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components  Journal Articles
• Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1  Journal Articles
• Transmission of hepatitis C with pasteurised factor VIII  Journal Articles
• Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate^®, a new generation von Willebrand factor/factor VIII concentrate  Journal Articles
• Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A  Journal Articles
• Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010  Journal Articles
• Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A  Journal Articles
• Urokinase Therapy: Dosage Schedules and Coagulant Side Effects  Journal Articles
• Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma  Journal Articles
• Use of Segments for the Quality Control of the Factor VIII: Coagulant Activity of Fresh Frozen Plasma  Journal Articles
• Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A  Journal Articles
• Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII  Journal Articles
• Von Willebrand's Syndrome Presenting as an Acquired Bleeding Disorder in Association With a Monoclonal Gammopathy  Journal Articles
• [Elimination of antibodies against coagulation factor VIII: Factor VIIa is the most promising therapeutic alternative].  Journal Articles
• [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].  Journal Articles